- Home
- SPNS vs AUPH Comparison
SPNS vs AUPH Comparison
Compare SPNS & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPNS
- AUPH
- Stock Information
- Founded
- SPNS 1982
- AUPH 1993
- Country
- SPNS Israel
- AUPH Canada
- Employees
- SPNS N/A
- AUPH N/A
- Industry
- SPNS Computer Software: Prepackaged Software
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- SPNS Technology
- AUPH Health Care
- Exchange
- SPNS Nasdaq
- AUPH Nasdaq
- Market Cap
- SPNS 1.6B
- AUPH 1.4B
- IPO Year
- SPNS 1992
- AUPH 1999
- Fundamental
- Price
- SPNS $42.77
- AUPH $12.27
- Analyst Decision
- SPNS Hold
- AUPH Strong Buy
- Analyst Count
- SPNS 3
- AUPH 4
- Target Price
- SPNS $31.33
- AUPH $12.25
- AVG Volume (30 Days)
- SPNS 1.9M
- AUPH 2.8M
- Earning Date
- SPNS 08-13-2025
- AUPH 07-31-2025
- Dividend Yield
- SPNS 1.40%
- AUPH N/A
- EPS Growth
- SPNS N/A
- AUPH N/A
- EPS
- SPNS 1.22
- AUPH 0.42
- Revenue
- SPNS $549,037,000.00
- AUPH $260,111,000.00
- Revenue This Year
- SPNS $8.25
- AUPH $12.15
- Revenue Next Year
- SPNS $6.85
- AUPH $18.34
- P/E Ratio
- SPNS $35.05
- AUPH $29.19
- Revenue Growth
- SPNS 3.08
- AUPH 25.59
- 52 Week Low
- SPNS $23.69
- AUPH $6.42
- 52 Week High
- SPNS $42.87
- AUPH $12.53
- Technical
- Relative Strength Index (RSI)
- SPNS 85.74
- AUPH 75.72
- Support Level
- SPNS $26.14
- AUPH $11.74
- Resistance Level
- SPNS $42.75
- AUPH $12.53
- Average True Range (ATR)
- SPNS 0.55
- AUPH 0.44
- MACD
- SPNS 1.23
- AUPH -0.00
- Stochastic Oscillator
- SPNS 99.43
- AUPH 80.74
About SPNS Sapiens International Corporation N.V. (Cayman Islands)
Sapiens International Corp NV is a provider of software solutions for the insurance industry, with an emerging focus on the financial services sector. The company offers software, solutions, and professional services for property & casualty (P&C); reinsurance; life, pension & annuity (L&A); workers' compensation (WC); medical professional liability (MPL); financial & compliance (F&C); and decision modeling for both insurance and financial markets. The group also provides services for project delivery and implementation services, for its Software Solutions portfolio. Geographically, it operates in the region of North America, Rest of the World, and Europe. It generates revenue from Europe.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.